| |
Tuesday, October 11, 2022 | 10am ET / 7am PT Join us to learn about common pitfalls for rAAV processing and ways to overcome the challenges. Key for a successful process are high viral genome productivity and full capsids in the harvest material, with high overall yield and efficient impurity removal. Register now.
|
|
Today's Big NewsOct 4, 2022 |
| By Nick Paul Taylor Pfizer has delivered a split decision on Voyager Therapeutics’ capsids. After spending one year assessing the capsids, the Big Pharma has paid $10 million to take up its option to use the gene therapy technology against a rare neurological disease target but backed out of the cardiovascular part of the deal. |
|
|
|
By James Waldron KalVista Pharmaceuticals' share price has been cut in half after the company scrapped one of its hereditary angioedema programs in the face of multiple reports of raised enzyme levels. |
By Max Bayer With the $11.6 billion sale to Pfizer officially behind it, Biohaven is directing clinical aspirations toward its epilepsy program. But to chart a new path, it will need to shake off consecutive late-stage losses. |
By Gabrielle Masson Bristol Myers Squibb is partnering up with San Francisco biotech SyntheX to ride into the lawless land of molecular glue degrader discovery—all while giving the biotech the potential to pocket up to $550 million in biobucks. |
By Nick Paul Taylor Sanofi has joined the scrum of drug developers targeting one of the biggest unmet needs in muscular dystrophy, committing to $30 million in upfront and near-term payments for global rights to miRecule’s preclinical prospect. |
By Max Bayer Flagship-founded Cellarity has tacked on $121 million in series C funds, tallying $274 million in total fundraising since launching in late 2019. |
By Gabrielle Masson Bristol Myers Squibb is looking for a light bulb moment, inking a deal with Autolus Therapeutics that gives the big pharma access to the biotech’s safety switch for cell therapy programs. |
By Helen Floersh Scientists have identified a new set of non-opioid molecules that ease pain without sedation. Their hope is that the drugs can be used alongside opioids, lowering the dose needed for relief. |
By Fraiser Kansteiner After Israeli-American copycat drug giant Teva in July petitioned the U.S. Supreme Court to overturn its $235 million loss in the long-running patent kerfuffle with GSK, the High Court has asked the Biden administration for its opinion on whether to reconsider the verdict. |
By Conor Hale The compact DASH system, developed in part by researchers at Northwestern University’s Feinberg School of Medicine, aims to deliver results within 15 minutes. |
By Frank Diamond Studies have yet to capture how racial and ethnic minorities fare in MA compared to traditional Medicare, according to a new KFF literature review. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk with many of the Fierce 15 honorees to find out what makes them unique. We also share highlights from the Fierce Biotech Summit on gene editing innovations and battling biotech's bear market. |
|
|---|
|
|
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT Data |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
| eBookImprove patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
| Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
